NRG Therapeutics Secures £50M In Series B Round

The Series B round includes an £8 million investment from the British Business Bank, with lead participation from SV Health Investors’ Dementia Discovery Fund (DDF) and follow-on funding from M Ventures, Novartis Venture Fund, Criteria Bio Ventures, and existing investors Omega Funds and Brandon Capital.

The funds will advance NRG Therapeutics from pre-clinical to clinical stages, focusing on proof-of-concept trials in amyotrophic lateral sclerosis (ALS/MND) and generating initial clinical data in Parkinson’s disease.

NRG Therapeutics, founded to tackle neurodegenerative diseases, is developing small molecule inhibitors targeting the mitochondrial permeability transition pore (mPTP), linked to cell death and neuroinflammation. Its lead candidate, NRG5051 has demonstrated neuroprotective effects in pre-clinical ALS/MND and Parkinson’s models, including reduced neuroinflammation and is set for first-in-human trials in early 2026.

Read Also - Renewcast Raises €1 Million To Advance Renewable Energy Forecasting Technology

“The pathological proteins in Parkinson’s and ALS/MND are toxic to mitochondria and contribute to the mitochondrial dysfunction which is a common underlying pathology in neurodegenerative diseases,” the company stated. “Inhibition of mPTP opening has been shown to protect mitochondria from this gain-of-function protein toxicity and to preserve neurons in pre-clinical models.”

Neurodegenerative diseases remain among the most challenging areas for drug development. Despite high clinical trial failure rates, the rising prevalence of conditions such as ALS and Parkinson’s especially in aging populations draws investors pursuing scalable scientific innovations with lasting impact.

“Developing new drugs to treat neurological diseases is very challenging but is receiving increased interest given the high unmet medical need and growing prevalence in aging populations,” said Dr. Neil Miller, co-founder and CEO of NRG Therapeutics. “These new funds provide the runway to advance our lead programme through PoC in ALS/MND, and to develop our portfolio of small molecule candidate drugs for other indications including Parkinson’s, offering new hope to the growing number of people and their families impacted by ALS/MND and Parkinson’s.”

“We seek to back the best of UK life sciences, helping to turn breakthrough research into world-leading, fully commercial companies,” said Leandros Kalisperas, Chief Investment Officer at British Business Bank. “Like many of our life sciences investments, our investment in NRG Therapeutics is especially rewarding because it has the potential to help find a solution to one of the world’s largest healthcare challenges.”

Following the Series B round, Emma Johnson (British Business Bank), Laurence Barker (SV Health Investors), Charlotte Kremers (M Ventures), and Florian Muellershausen (Novartis Venture Fund) will join NRG’s board, providing strategic industry expertise as the company advances into clinical development.

About NRG Therapeutics

NRG Therapeutics is creating therapies that target mitochondria to treat neurodegenerative diseases with the goal of slowing or stopping disease progression. Its lead drug, NRG5051 has shown protective effects in early studies for ALS and Parkinson’s. The company is now preparing for its first human trials to tackle these urgent medical needs.